MyFinsight
Home
Blog
About
Proceeds from issuance of
common stock and...
$281,400K
Net cash provided by
financing activities
$211,071K
(144.40%↑ Y/Y)
Canceled cashflow
$70,329K
Net increase
(decrease) in cash and cash...
-$34,593K
(-123.66%↓ Y/Y)
Canceled cashflow
$211,071K
Proceeds from sales and
maturities of investments
$67,660K
(-52.88%↓ Y/Y)
Stock-based compensation
expense
$2,788K
(-63.22%↓ Y/Y)
Accrued expenses and
other liabilities
$1,391K
(167.39%↑ Y/Y)
Impairment loss on
long-lived asset
$783K
Amortization of debt discount
and costs
$237K
(308.62%↑ Y/Y)
Depreciation of property and
equipment
$23K
(-61.02%↓ Y/Y)
Loss on foreign
currency exchange
-$22K
(26.67%↑ Y/Y)
something is missing
-$69,731K
Other financing
activities
-$509K
Proceeds from issuance of
common stock in...
-$89K
(-100.12%↓ Y/Y)
Net cash used in
investing activities
-$221,443K
(-330.66%↓ Y/Y)
Canceled cashflow
$67,660K
Net cash used in
operating activities
-$24,221K
(33.07%↑ Y/Y)
Canceled cashflow
$5,244K
Purchases of investments
$289,071K
(507.64%↑ Y/Y)
Purchases of property and
equipment
$32K
(220.00%↑ Y/Y)
Net loss
-$22,825K
(45.29%↑ Y/Y)
Prepaid expenses and
other assets
$3,722K
(96.41%↑ Y/Y)
Accounts receivable
$1,676K
(851.57%↑ Y/Y)
Accretion of discounts on
investments
$984K
(-11.91%↓ Y/Y)
Accounts payable
-$258K
(-140.31%↓ Y/Y)
Back
Back
Cash Flow
Altimmune, Inc. (ALT)
Altimmune, Inc. (ALT)
source: myfinsight.com